Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Steven Messina,L.M.T. who wrote (28193)	12/15/1998 10:53:00 AM
From: brent gephart	Respond to of 119973

MEDC: The $4 range is a good price. SHORT TERM: The stock deal is just the icing on the cake. The fact that B&D want's the rights to these needles is excellent. That means they see how good the technology is and know that they can not make something better. B&D BDX is the 500 pound gorilla in the diabetes and drug delivery market place, which makes this deal so good for MEDC. Plus the company only has 7 million outstanding 4 million float LONG TERM: The company has its own clean room and can make the needles for B&D. Also with all of the needs being used as delivery mechanisms for immunizations in third would countries MEDC delivery system will work great. Reason being they can only use the need once because it does not work a second and therefore can not be used to either stick the delivery person or be used on multiple people as often happen in third world countries. Brent